ReviewCell communication and signaling : CCS2026
The multidimensional signaling of ELANE: from congenital hematopoietic failure to immune microenvironment crosstalk and targeted interventions.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the neutrophil elastase gene (ELANE) have classically been established as the primary genetic etiology of severe congenital neutropenia (SCN) and cyclic neutropenia (CyN), characterized by early-stage granulocytic maturation arrest and a predisposition to life-threatening infections. However, recent high-throughput transcriptomic, multi-omics, and functional studies have unveiled a paradigm-shifting, multidimensional role for neutrophil elastase (NE) that extends far beyond the confines of bone marrow failure. As a highly active serine protease, NE has emerged as a central hub in regulating recently discovered forms of regulated cell death (RCD), including pyroptosis, ferroptosis, and NETosis, and orchestrating the tumor immune microenvironment (TIME). Within the bone marrow, mutant NE triggers intense proteotoxic stress, reactive oxygen species (ROS) accumulation, and a unique proapoptotic "aggrephagy" (the selective autophagic degradation of misfolded protein aggregates), driving granulocyte colony-stimulating factor (G-CSF) resistance and clonal evolution toward acute myeloid leukemia (AML). Extracellularly, NE released via neutrophil extracellular traps (NETs) acts as a fascinating double-edged sword: it possesses the intrinsic capability to selectively eradicate genetically diverse cancer cells by cleaving the CD95 death domain and interacting with histone H1 isoforms, yet it concomitantly mediates immunosuppression, chemoresistance, and systemic inflammatory response syndrome (SIRS) in sepsis by reprogramming macrophage polarization. This review systematically synthesizes the intricate molecular mechanisms of NE, emphasizing the profound crosstalk between hematopoietic failure, inflammatory cell death pathways, and tumor immunology. Furthermore, this review highlights the translational potential of these discoveries, exploring cutting-edge therapeutic strategies, including CRISPR/Cas9-based precise base editing, dual-nickase promoter targeting, and selective allosteric small-molecule inhibitors, ultimately aiming to bridge the critical gaps from bench to bedside.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.